Compare SHO & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHO | NTLA |
|---|---|---|
| Founded | 1995 | 2014 |
| Country | United States | United States |
| Employees | 37 | N/A |
| Industry | Hotels/Resorts | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | N/A | 2016 |
| Metric | SHO | NTLA |
|---|---|---|
| Price | $11.36 | $17.38 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 23 |
| Target Price | $9.79 | ★ $20.02 |
| AVG Volume (30 Days) | 3.1M | ★ 6.7M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.66% | N/A |
| EPS Growth | N/A | ★ 27.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,671,000.00 |
| Revenue This Year | $3.95 | N/A |
| Revenue Next Year | $2.30 | $62.75 |
| P/E Ratio | $966.33 | ★ N/A |
| Revenue Growth | N/A | ★ 16.92 |
| 52 Week Low | $8.52 | $7.95 |
| 52 Week High | $12.07 | $28.24 |
| Indicator | SHO | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 49.80 | 69.19 |
| Support Level | $8.81 | $11.73 |
| Resistance Level | $12.07 | $27.61 |
| Average True Range (ATR) | 0.26 | 1.21 |
| MACD | -0.11 | 0.28 |
| Stochastic Oscillator | 23.04 | 84.38 |
Sunstone Hotel Investors Inc is a real estate investment trust that acquires, owns, manages, and renovates the full-service hotel and select-service hotel properties across various states in the United States. Its firm's portfolio consists upper upscale and luxury hotels located in convention, resort destination and urban markets. Its majority of the hotels operate under a brand owned by Marriott, Hilton, Hyatt, Four Seasons or Montage. It operates geographically in California which generates the majority of its revenue; Florida; and Hawaii. The company's sole source of income is hotel revenue from its Hotel Ownership Segment.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.